Performance VerificationNCT07921979
Clinical Application Research Plan for Fully Automated Sample Processing System
An observational study of Performance Verification, run by BangShun He.
Trial summary
By utilizing the fully automated sample processing system from Xiamen U-Medical Instruments Co., Ltd. (compatible with the Wan200+/Wan600+ fully automatic chemiluminescent immunoassay systems and the Wan BC2800 fully automatic biochemical analyzer), serum, plasma, urine, or other bodily fluid samples are processed… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Performance Verification
- What is being tested?
- performance verification
- How many people
- 2,900 participants
- Where
- No sites listed yet
- Study dates
- 30 Nov 2026to 31 Dec 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Study population: No restrictions on audience
Who may be able to join
- During the research period, according to the clinical application research plan of the fully automated sample processing system, the remaining clinical test samples that match the test results or corresponding clinical diagnoses were selected, including but not limited to serum, plasma, urine, etc.
Who cannot join
- Samples that do not meet the inclusion criteria;
- Samples with unclear clinical diagnosis;
- Test samples that are severely hemolyzed, deteriorated, contain chylous blood, or are significantly contaminated by microorganisms, etc., and do not meet the requirements.
- Removal Criteria
- Sample results that do not meet the inclusion criteria or for which exclusion criteria were met but testing was still conducted;
- Samples that did not complete the required tests for the complete trial or had missing data due to sample or instrument operation;
- When test samples require re-testing due to human error, instrument failure, sample addition failure, etc., the re-tested results shall be taken as the standard, and the reasons for re-testing shall be recorded.
About this study
By utilizing the fully automated sample processing system from Xiamen U-Medical Instruments Co., Ltd. (compatible with the Wan200+/Wan600+ fully automatic chemiluminescent immunoassay systems and the Wan BC2800 fully automatic biochemical analyzer), serum, plasma, urine, or other bodily fluid samples are processed automatically throughout the entire workflow, covering pre-analytical, analytical, and post-analytical stages.
A systematic evaluation is conducted on the system's functional performance, user satisfaction, ease of operation, and stability during use.
Read more
Key performance indicators such as turnaround time (TAT) and sample throughput are assessed through node monitoring and recording across the entire sample processing workflow.
Statistical analysis is performed on the system's failure rate, maintenance requirements, and emergency response capabilities under continuous operation conditions.
- Conditions
- Performance Verification
- Being tested
- performance verification
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
performance verificationOther
By utilizing the fully automated sample processing system from Xiamen U-Medical Instruments Co., Ltd. (compatible with the Wan200+/Wan600+ fully automatic chemiluminescent immunoassay systems and the Wan BC2800 fully automatic biochemical analyzer), serum, plasma, urine, or other bodily fluid samples are processed automatically throughout the entire workflow, covering pre-analytical, analytical, and post-analytical stages.
A systematic evaluation is conducted on the system's functional performance, user satisfaction, ease of operation, and stability during use.
Key performance indicators such as turnaround time (TAT) and sample throughput are assessed through node monitoring and recording across the entire sample processing workflow.
Statistical analysis is performed on the system's failure rate, maintenance requirements, and emergency response capabilities under continuous operation conditions.
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluate the sample turnaround time
Measured: 202611.01-2030.12.31
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Nov 2026
- Study start30 Nov 2026 (estimated)
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Performance VerificationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 2,900 participants (estimated)
Sponsor and investigators
- Lead sponsor
- BangShun He
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, BangShun He, Nanjing First Hospital, Nanjing Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07921979
- Sponsor's protocol ID
- NanjingFirst-LAB-02
- Status last verified
- Nov 2026
- First submitted
- 2 Nov 2026
- Last updated
- 6 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Application Research Plan for Fully Automated Sample Processing System
- ClinicalTrials.gov ID
- NCT07921979
- Acronym / sponsor ID
- NanjingFirst-LAB-02
- Conditions
- Performance Verification
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 2,900 participants (estimated)
- Lead sponsor
- BangShun HeUniversity, hospital or other
- Study start
- 30 Nov 2026 (estimated)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2030 (estimated)
- First posted
- 6 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
By utilizing the fully automated sample processing system from Xiamen U-Medical Instruments Co., Ltd. (compatible with the Wan200+/Wan600+ fully automatic chemiluminescent immunoassay systems and the Wan BC2800 fully automatic biochemical analyzer), serum, plasma, urine, or other bodily fluid samples are processed automatically throughout the entire workflow, covering pre-analytical, analytical, and post-analytical stages.
A systematic evaluation is conducted on the system's functional performance, user satisfaction, ease of operation, and stability during use.
Key performance indicators such as turnaround time (TAT) and sample throughput are assessed through node monitoring and recording across the entire sample processing workflow.
Statistical analysis is performed on the system's failure rate, maintenance requirements, and emergency response capabilities under continuous operation conditions.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- No restrictions on audience
Key inclusion criteria (1 listed)
- During the research period, according to the clinical application research plan of the fully automated sample processing system, the remaining clinical test samples that match the test results or corresponding clinical diagnoses were selected, including but not limited to serum, plasma, urine, etc.
Key exclusion criteria (7 listed)
- Removal Criteria
- Sample results that do not meet the inclusion criteria or for which exclusion criteria were met but testing was still conducted;
- Samples that did not complete the required tests for the complete trial or had missing data due to sample or instrument operation;
- When test samples require re-testing due to human error, instrument failure, sample addition failure, etc., the re-tested results shall be taken as the standard, and the reasons for re-testing shall be recorded.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| performance verificationBy utilizing the fully automated sample processing system from Xiamen U-Medical Instruments Co., Ltd. (compatible with the Wan200+/Wan600+ fully automatic chemiluminescent immunoassay systems and the Wan BC2800 fully automatic biochemical analyzer), serum, plasma, urine, or other bodily fluid samples are processed automatically throughout the entire workflow, covering pre-analytical, analytical, and post-analytical stages. A systematic evaluation is conducted on the system's functional performance, user satisfaction, ease of operation, and stability during use. Key performance indicators such as turnaround time (TAT) and sample throughput are assessed through node monitoring and recording across the entire sample processing workflow. Statistical analysis is performed on the system's failure rate, maintenance requirements, and emergency response capabilities under continuous operation conditions. | Other | – |
Primary outcome
Evaluate the sample turnaround time
Time frame: 202611.01-2030.12.31
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
- Individual participant dataSharing planned: No
Related trials for Performance Verification
Not yet recruitingObservational study
Clinical Application Research of the Fully Automatic Biochemical System
Performance Verification
Not yet recruitingObservational study
Clinical Application Research Plan for Fully Automated Chemiluminescent Immunoassay Reagents
Performance Verification
Not yet recruiting
DeepMedFake-Assisted Detection of Synthetic and Discordant Medical Images
Medical Image Integrity Verification
Recruiting
Product Information Analysis and Clinical Verification - Clinical Verification of New Smart Health Medical Shoes/Insoles
Pronated Foot
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Performance Verification, run by BangShun He.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluate the sample turnaround time (time frame: 202611.01-2030.12.31). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.